Eli Lilly
Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure
April 20, 2016Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly
Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …
Eli Lilly drops development of diabetes drug in Phase III
April 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial
US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
Incyte buys rights to Eli Lilly’s Ruxolitinib; shares jump
April 7, 2016Research and Development, Sales and Marketing Eli Lilly, Incyte, Licencing, M&A, MA, Novartis
Shares in Incyte Corp (Nasdaq: INCY) soared to close up over 11.5% Wednesday as the company said it has purchased …
Sun to cut jobs in Irish facility closure; Lilly announce further investment in the country
April 6, 2016Manufacturing and Production, Research and Development Eli Lilly, Ireland, Kinsale, Sun Pharma, cashel, investment, lilly
There was mixed news for pharmaceutical manufacturing in Ireland as Sun Pharma announced its decision to close its facility based …
Lilly’s RA drug baricitinib meets Phase III goals
March 31, 2016Research and Development Eli Lilly, Incyte, rheumatoid arthritis
Eli Lilly and Incyte have announced the publication of detailed Phase III trial results from a study of their biologic …
FDA approves Lilly’s plaque psoriasis drug Taltz
March 23, 2016Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis
The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …
Lilly changes Alzheimer’s trial endpoint – shares fall
March 16, 2016Research and Development Alzheimer's disease, Eli Lilly, solanezumab
Shares in Eli Lilly fell more than 4% yesterday when it announced it was changing the primary endpoint of a closely-watched …
Adocia and Lilly report positive early results for ultra-rapid insulin
March 15, 2016Manufacturing and Production, Research and Development Adocia, BioChaperone Lispro, Eli Lilly, insulinm
Eli Lilly and development partner Adocia have announced today positive topline results from a Phase 1b clinical trial of ultra-rapid …
Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials
March 7, 2016Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis
Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …
CHMP recommends Lilly psoriasis drug for approval
February 29, 2016Research and Development Eli Lilly, Taltz, psoriasis
Eli Lilly’s Taltz (ixekizumab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
European Commission approves Lilly’s Portrazza for NSCLC
February 24, 2016Research and Development Eli Lilly, Portrazza
The European Commission has approved Eli Lilly’s Portrazza (necitumumab), in combination with gemcitabine and cisplatin chemotherapy, as a first-line treatment …
Lilly suffers damaging Alimta patent blow
February 15, 2016Manufacturing and Production, Sales and Marketing Actavis, Alimta, Allergan, Eli Lilly, pemetrexed
Eli Lilly says it plans to appeal a UK High Court’s verdict that could imminently open its blockbuster lung cancer …
Biosimilars: Can the US catch up in 2016?
February 12, 2016Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars
What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …
FDA reviews Jardiance as cardiovascular diabetes treatment
January 27, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance
The FDA has accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for their diabetes drug Jardiance to be …
Lilly awaits FDA review of new arthritis treatment
January 20, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis
Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …
Latest content
Five Facts about cardiovascular disease
